Lei Diao
1289 Yishan Road
Shanghai, 200233, China
Shanghai, 200233, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Pharmacokinetics, safety, and pharmacodynamics of intravenous methoxyethyl etomidate hydrochloride (ET-26-HCl) in Chinese participants with hepatic impairment.
Journal: Frontiers in pharmacology
Published: March 11, 2026
KDM4A serves as an α-tubulin demethylase regulating microtubule polymerization and cell mitosis.
Journal: Science advances
Published: October 31, 2025
Pharmacokinetics and safety of HR17031, a fixed-ratio of INS068/Noiiglutide combination, in Chinese patients with hepatic impairment.
Journal: Diabetes, obesity & metabolism
Published: October 27, 2025
Pharmacokinetics, safety, and tolerability of nacubactam (OP0595) after intravenous infusion: a randomized, double-blind, placebo-controlled phase I clinical trial in healthy Chinese male subjects.
Journal: Clinical and experimental medicine
Published: September 01, 2025
Screening the composition of tubulin isotypes reveals the most abundant TUBB4B for ciliary polarity in ependymal cells.
Journal: Journal of molecular cell biology
Published: August 15, 2025
Pharmacokinetics, mass balance, and metabolism of [14C]SAF-189s, a potent anaplastic lymphoma kinase/c-ROS proto-oncogene 1 inhibitor in humans: Metabolism potentially affected by interaction of cytochrome P450 enzymes and intestinal microbiota.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: May 01, 2025
TUBA8 promotes neuronal dendrite development through its 40th alanine.
Journal: Journal of molecular cell biology
Published: March 03, 2025
Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans.
Journal: Cancer chemotherapy and pharmacology
Published: February 22, 2025
The pharmacokinetics and Concentration-QTc analysis of a new etomidate analog ET-26-HCl: a phase I trial in healthy Chinese subjects.
Journal: Frontiers in pharmacology
Published: November 26, 2024
No QTc prolongation with CDK 4/6 inhibitor FCN-437c: results of a concentration-QTc analysis from a dedicated study in adult healthy subjects.
Journal: Frontiers in pharmacology
Published: May 16, 2024
Population pharmacokinetics and exposure-response analyses of SAF-189s in Chinese patients with ALK+/ROS1+ non-small cell lung cancer.
Journal: Frontiers in pharmacology
Published: April 16, 2024
Population pharmacokinetic model for oral ORIN1001 in Chinese patients with advanced solid tumors.
Journal: Frontiers in pharmacology
Published: October 16, 2023
Last Updated: 09/26/2026